Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorAl-Heibshy, Fawaz N. S.
dc.contributor.authorBaşaran, Ebru
dc.contributor.authorDemirel, Müzeyyen
dc.date.accessioned2019-10-22T20:06:50Z
dc.date.available2019-10-22T20:06:50Z
dc.date.issued2016
dc.identifier.issn0326-2383
dc.identifier.urihttps://hdl.handle.net/11421/22078
dc.descriptionWOS: 000383364400001en_US
dc.description.abstractCardiovascular diseases are the leading causes of death worldwide and rosuvastatin calcium (RCa) is one of the most effective drugs used for the prevention of coronary heart diseases. Considering low aqueous solubility oral bioavailability of RCa was hardly reached to almost 20%. Therefore there is still a demand for novel drug delivery systems with outstanding drug absorption, distribution, and elimination rates as well as less side effects. In this study RCa was incorporated into chitosan acetate (CA), chitosan lactate (CL), chitosan aspartate (CAs) and chitosan glutamate (CG) nanoparticles (NPs) for the enhancement of its preferential use. Spray drying method was used for the formation of the RCa incorporated NPs. Physicochemical characteristic properties were evaluated in detail and analyses results demonstrated that particle sizes were ranged between 240.0 +/- 10.7-446.9 +/- 13.1 nm with homogenous size distributions (with PDI data range of 0.490 +/- 0.032 to 0.790 +/- 0.090) while the zeta potentials mostly valued in the cationic scale. Entrapment efficiencies (EE) of RCa-CA-NPs and RCa-CL-NPs were the highest with 80.8 +/- 3.1% and 99.1 +/- 1.9%, respectively. In vitro release study results demonstrated initial burst releases for the RCa-CA-NPs and RCa-CL-NPs with almost 58% just within 5 min while the release rate of pure RCa was reached up to 53% in phosphate buffer solution (pH 6.8) only after 1 h. As a result of the study enhanced in vitro release rates were achieved from RCa incorpotared NPs showing that the chitosan (Cs) originated NPs have the potentials as novel drug delivery systems for RCa.en_US
dc.description.sponsorshipAnadolu University Scientific Research Project Foundation [1404S289]en_US
dc.description.sponsorshipThis study was supported by Anadolu University Scientific Research Project Foundation (No: 1404S289). The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.en_US
dc.language.isoengen_US
dc.publisherColegio Farmaceuticos Provincia De Buenos Airesen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChitosanen_US
dc.subjectChitosan Saltsen_US
dc.subjectDrug Releaseen_US
dc.subjectNanoparticlesen_US
dc.subjectRosuvastatin Calciumen_US
dc.titleStudies on Rosuvastatin Calcium Incorporated Chitosan Salt Nanoparticlesen_US
dc.typearticleen_US
dc.relation.journalLatin American Journal of Pharmacyen_US
dc.contributor.departmentAnadolu Üniversitesi, Sağlık Bilimleri Enstitüsü, Farmasötik Teknolojisi Anabilim Dalıen_US
dc.identifier.volume35en_US
dc.identifier.startpage1065en_US
dc.identifier.endpage1076en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US]
dc.contributor.institutionauthorDemirel, Müzeyyen


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster